The vicious cycle of SASP and inflammaging promotes aging and age-related diseases Authors: Qian Liu, Yulin Zheng, Chongkui Sun Published: 2026 ABSTRACT AbstractSenescent cells accumulate in aging tissues and secrete a complex array of bioactive factors that alter the surrounding environment. While transient signaling can support tissue repair, persistent activity drives chronic low-grade inflammation and contributes to age-related diseases. These factors can spread damage to nearby cells and disrupt immune balance, creating a self-reinforcing cycle. We integrate these features into a three‑dimensional framework of duality, vicious cycle, and tissue specificity to guide context‑matched therapy. This review discusses how senescent cells influence tissue function during aging, the mechanisms underlying their harmful effects, and emerging strategies to limit these effects.Subject terms: Senescence, Mechanisms of disease Introduction With the extension of human lifespan and the growing aging population, age-related chronic diseases have become a major global health concern1. Cellular senescence, a state of stable and irreversible cell cycle arrest, is widely recognized as a fundamental hallmark of aging2–4. It can be triggered by diverse stressors, including DNA damage, telomere shortening, oxidative stress, oncogene activation, and epigenetic alterations3,5,6. One of the most well-characterized features of senescent cells is the senescence-associated secretory phenotype (SASP), defined as the sustained secretion of a wide range of bioactive molecules, including pro-inflammatory cytokines, chemokines, growth factors, and proteases (Table 1)3,7,8. In early life, cellular senescence serves beneficial roles in tumor suppression and wound healing, partly through SASP-mediated recruitment of immune cells for tissue remodeling and clearance of damaged cells7,8. However, in the context of organismal aging, senescent cells accumulate and SASP factors are chronically produced, imposing a pro-inflammatory milieu on tissues4,9,10. Table 1Representative SASP factors and their functions in inflammagingCategoryRepresentative SASP FactorsPrimary Functions in InflammagingRef.Pro-inflammatory CytokinesIL-6, IL-1α/β, TNF-αRecruit immune cells, promote chronic inflammation and reinforce senescence30ChemokinesIL-8 (CXCL8), CCL2, CCL5, CXCL1Attract neutrophils/monocytes/T cells, contribute to chronic immune cell infiltration4,14ProteasesMMP-1/3/9/13, ADAMTS4/5, ADAM17ECM degradation, cause tissue remodeling and damage, promote tumor invasion22,59,168Growth factorsTGF-β, VEGF, HB-EGF, EGF, FGF2, PDGF, HGFTGF-β promotes fibrosis; VEGF stimulates angiogenesis; both can propagate senescence7,73Pro-fibrotic FactorsCTGF, PAI-1Stimulate collagen deposition, accelerate organ fibrosis (liver/lung/kidney)169Other mediatorsHMGB1, ROS, PGE2, mtDNAFunction as DAMPs or paracrine senescence/pain mediators147,170,171SASP Senescence-Associated Secretory Phenotype, ECM Extracellular Matrix, DAMPs damage-associated molecular patterns. Representative SASP factors and their functions in inflammaging SASP Senescence-Associated Secretory Phenotype, ECM Extracellular Matrix, DAMPs damage-associated molecular patterns. The concept of inflammaging was first proposed by Franceschi et al. in 2000 to describe the chronic, low-grade, sterile inflammation observed in aging organisms11. Inflammaging is characterized by elevated levels of systemic inflammatory markers, such as IL-6, IL-1, TNF-α, and C-reactive protein (CRP) in older individuals even in the absence of infection11,12. Subsequent studies have revealed that SASP is a key driver of inflammaging10,13,14. In addition to reinforcing growth arrest in an autocrine manner, SASP factors exert profound paracrine effects, inducing senescence in neighboring cells, recruiting immune cells, and reshaping tissue microenvironments10,14–16. In this review, we systematically summarize the upstream signaling pathways and regulatory factors controlling SASP production, and then elucidate their links to aging phenotypes and disease progression. We also discuss the challenges and therapeutic prospects of targeting SASP in age-related pathologies. Understanding the regulatory networks of SASP and its context-specific roles, particularly how these mechanisms drive pathological processes, is critical for developing targeted interventions to improve healthspan and treat aging-associated diseases. A central theme of this review is the integration of three dimensions, including the dual‑edged sword nature of SASP, its self‑reinforcing cycle with inflammaging, and its tissue‑specific effects, which together provide a novel framework for understanding SASP pathology and guiding rational therapy. Senescence-associated secretory phenotype (SASP) and inflammaging Features and functional duality of SASP Previous studies have shown that the SASP exhibits context-dependent and temporally dynamic effects that are both beneficial and detrimental17. In the early stages of senescence, SASP can play a protective role by promoting the recruitment of immune cells, such as macrophages and natural killer (NK) cells, to recognize and eliminate damaged or potentially pre-malignant cells, thereby acting as a barrier to tumorigenesis8,18. In addition, certain SASP components, including VEGF and PDGF-AA, contribute to tissue remodeling and regeneration by supporting wound healing and stimulating angiogenesis19–21. However, when senescent cells persist and SASP remains chronically active, its role shifts from protective to pathogenic. Prolonged SASP expression fosters a pro-inflammatory microenvironment characterized by elevated levels of IL-6, IL-8, matrix metalloproteinases (MMPs), and other inflammatory mediators, which can lead to chronic tissue inflammation, stem cell exhaustion, and functional decline of various organs5,22. Furthermore, persistent SASP has been implicated in creating a tumor-promoting microenvironment that facilitates malignant transformation, tumor progression, metastasis, and even resistance to therapy17,23,24. Collectively, this dual nature of SASP highlights the need for temporal and spatial regulation in therapeutic strategies targeting senescent cells and their secretory profiles (Fig. 1). Overview of SASP and its dual roles in aging and disease. Senescent cells secrete a complex array of bioactive factors collectively known as the senescence-associated secretory phenotype (SASP), including cytokines (e.g., IL-6, IL-8, IL-17, TGF-β), chemokines, growth factors, and matrix-remodeling enzymes (e.g., VEGF, MMPs). SASP exerts context-dependent effects: transient SASP (blue panel) promotes beneficial outcomes such as immune cell recruitment and clearance of damaged cells, tumor suppression, tissue repair and regeneration, wound healing, angiogenesis, and prevention of fibrosis. In contrast, persistent SASP (yellow panel) drives detrimental consequences, including tumor promotion, cell proliferation and invasion, malignant transformation, angiogenesis, therapy resistance, stem cell exhaustion, chronic inflammation, inflammaging, and progressive organ decline. This dualistic nature highlights SASP as a double-edged sword in aging and age-related diseases. (Created in BioRender. liu, Q. (2026) https://BioRender.com/jt46mwk). Overview of inflammaging Unlike acute inflammation triggered by infection, inflammaging is driven by a constellation of endogenous and exogenous factors, including immune dysfunction, cellular senescence, metabolic imbalance, and changes in the microbiota25. It is recognized as a major pathological underpinning of numerous age-related diseases, including cardiovascular disease, type 2 diabetes, sarcopenia, and neurodegenerative disorders like Alzheimer’s disease12,13,26. The development of inflammaging is a multifactorial process involving several interconnected mechanisms, including decline in immune function, known as immunosenescence16, activation of inflammatory pathways such as NF-κB27, mitochondrial dysfunction and increased ROS generation28, metabolic and nutrient-sensing alterations29, and the accumulation of senescent cells and their SASP output7,8. Among these mechanisms, SASP is considered one of the major drivers of inflammaging (Table 1). The development of inflammaging is closely linked to age-associated immune dysfunction, particularly immunosenescence11. These two aging phenomena are mutually reinforcing and form the so-called immuno-inflammaging axis11. In recent years, inflammaging has been increasingly recognized as one of the emerging hallmarks of aging and a central therapeutic target for mitigating age-related functional decline30. The vicious cycle of SASP and inflammaging Mounting evidence indicates that SASP and inflammaging are not independent phenomena but deeply intertwined processes. SASP acts as both a driver and amplifier of inflammaging, whereas inflammaging, in turn, reinforces the induction and persistence of SASP. This bidirectional interaction provides a unifying framework for understanding how molecular damage in individual cells can translate into organismal aging and the onset of chronic, age-related diseases (Fig. 2). The vicious cycle between SASP and inflammaging. Senescent cells release a variety of SASP factors driving multiple pathological processes: (1) sustained secretion of pro-inflammatory cytokines that activate local and immune cells; (2) propagation of senescence via paracrine signaling; (3) recruitment and polarization of immune cells into pro-inflammatory states; and (4) persistent activation of innate immune pathways such as DDR, NF-κB, mTOR, and cGAS–STING, driving systemic cytokine production. These mechanisms promote immunosenescence and chronic low-grade inflammation, collectively leading to inflammaging. In turn, inflammaging reinforces SASP by inducing DNA damage, oxidative stress, and impaired immune clearance, thereby establishing a self-reinforcing cycle. This vicious cycle accelerates tissue degeneration, functional decline, and the onset of age-related diseases. (Created in BioRender. liu, Q. (2026) https://BioRender.com/x85ynyk). Priming a broader inflammatory response SASP represents one of the most critical sources of chronic inflammatory stimuli. Senescent cells secrete a complex array of SASP factors that collectively induce sustained, low-level inflammation at both local and systemic levels (Table 1)31. Through continuous release of pro-inflammatory mediators, SASP lowers the threshold for inflammatory activation and facilitates the propagation of cytokine signaling to neighboring cells and distant tissues32,33. This process amplifies inflammatory cascades and contributes to the establishment of a persistent inflammatory microenvironment characteristic of inflammaging14. Such sustained signaling can disrupt tissue homeostasis and is associated with the development of age-related pathologies34. Collectively, these features highlight SASP as a major contributor to the initiation and maintenance of inflammaging. Inducing paracrine senescence SASP exerts its effects not only through autocrine reinforcement of the senescent state but also via paracrine signaling, whereby adjacent non-senescent cells adopt a senescent phenotype, a process termed paracrine senescence33. In addition to acting locally, SASP factors may disseminate through the circulation, exerting influence on distant tissues and amplifying systemic inflammation8,35. Key components such as TGF-β, IL-1, IL-6 and IL-8 play multifaceted roles in this context. For instance, TGF-β and IL-6 promote cell senescence or dysfunction in surrounding proliferating cells, while IL-6 and IL-8 further stimulate resident stromal and immune cells to enhance cytokine production, thereby establishing a pro-inflammatory feedback loop32,33,36. Specifically, IL‑1α functions as a critical upstream regulator of SASP by activating NF-κB signaling in an autocrine manner, thereby enhancing the expression of downstream pro-inflammatory factors, particularly IL‑6 and IL‑8, reinforcing a self-sustaining positive feedback circuit that amplifies both autocrine and paracrine SASP signaling37. Accumulating evidence indicates that SASP activates several key pro-inflammatory signaling pathways, including NF-κB, p38 MAPK, and TAK1/Zscan4-mediated feedback loops27,37,38. These pathways reinforce and sustain the senescent state while promoting the spread of inflammation. Inflammasomes, particularly NLRP3, also play a central role by triggering IL-1-mediated amplification of inflammation and paracrine senescence33,39. This mechanistic framework helps explain how even a small number of senescent cells can initiate persistent and widespread inflammation. In addition, SASP-related DAMPs such as ROS and HMGB1 mediate bystander effects in adjacent cells, increasing the overall senescent cell burden in a tissue27,40,41. Animal studies confirm that transplantation of even a few senescent cells into young mice induces systemic degenerative changes and inflammation, supporting the notion that localized senescence can drive global inflammaging42–44. Thus, paracrine senescence serves as a potent amplifier, allowing a small population of senescent cells to propagate widespread inflammation and accelerate inflammaging. Recruitment of immune cells and inducing immunosenescence One key consequence of SASP factors is the recruitment of immune cells. Many SASP chemokines can attract leukocytes such as neutrophils, monocytes/macrophages, and NK cells to the sites of senescent cells15. Initially, this recruitment is thought to be beneficial because the immune cells, such as macrophages and NK cells, can help clear senescent cells. However, with a high load of senescent cells or an aged immune system, this clearance becomes inefficient, and the persistent presence of recruited immune cells contributes to sustained chronic inflammation10. SASP-activated macrophages further release IL-1β, IL-6, and TNF-α, amplifying the inflammatory cascade10. Prolonged SASP exposure can drive macrophages toward a pro-inflammatory activation state, perpetuating IL-6 and TNF-α secretion45. This process is accompanied by metabolic reprogramming, characterized by increased glycolysis and reduced mitochondrial oxidative phosphorylation (OXPHOS)46. Enhanced glycolysis supports rapid ATP generation and biosynthetic demands, while also promoting the accumulation of metabolites like succinate that stabilize inflammatory signaling pathways such as HIF-1α, thereby reinforcing pro-inflammatory cytokine production47. Together, these metabolic changes contribute to the persistence of inflammatory responses and establish a self-reinforcing metabolism-immunity-inflammation cycle48. SASP exposure also induces senescence in T and B lymphocytes and induces dysfunction in NK cells, thereby reducing immune surveillance, a phenomenon termed immunosenescence16. These immune deficits impair clearance of senescent cells, perpetuating a vicious cycle of inflammation, senescence, and immune suppression11. This self-perpetuating feedback loop in which SASP recruits immune cells that release more inflammatory mediators but fail to clear senescent cells is a central feature of inflammaging10. In short, SASP-driven immune recruitment and dysfunction generate an inflammatory-immunosenescent axis that perpetuates inflammaging. Persistent activation of innate immune pathways The persistent activation of innate immune pathways is another hallmark of SASP-driven inflammaging. Many SASP factors can activate pattern-recognition receptors (PRRs) and perpetuate inflammatory signaling via Toll-like receptors (TLRs), Nod-like receptors (NLRs), interferon pathways, and NF-κB14. SASP has been shown to upregulate TLR and interferon-stimulated genes (ISGs), driving systemic immune activation49. For example, previous studies have shown that IL-1α and TNF-α can activate NF-κB in both immune and non-immune cells, establishing a chronic inflammatory transcriptional program50. Moreover, senescent cells often release endogenous DAMPs such as HMGB1, genomic DNA fragments, and S100 proteins, which further activate TLRs and inflammasomes in immune cells51. In fact, persistent SASP signaling has been linked to priming of the NLRP3 inflammasome. Specifically, SASP cytokines such as IL-6 and TNF-α provide the first signal that upregulates inflammasome components in macrophages, while SASP-related stress signals like ROS provide the second signal for activation. This process ultimately leads to the release of IL-1β and IL-18, thereby amplifying inflammation52. Chronic IL-1β production is a common feature in aged tissues and is strongly pro-inflammatory, while the SASP of senescent cells, particularly through IL-1α, is a significant source of the IL-1 family cytokines that drive this process16,53. Therefore, SASP-induced innate immune activation transforms transient defense responses into a chronic inflammatory program central to inflammaging. The self-reinforcing cycle Ultimately, SASP-induced immune cell recruitment, bystander senescence, and innate immune activation converge to create persistent low-grade inflammation, a process known as inflammaging10. On one hand, SASP drives inflammaging by releasing pro-inflammatory mediators, chemokines, and matrix-degrading enzymes. These factors not only promote paracrine senescence in neighboring cells but also recruit and activate immune cells, establishing a chronic inflammatory microenvironment. Persistent SASP activity thereby lowers the threshold for inflammatory signaling and gradually establishes a systemic pro-inflammatory state characteristic of inflammaging. On the other hand, inflammaging reinforces SASP. Chronic, low-grade inflammation exposes tissues to continuous cytokine stimulation and oxidative stress, which in turn accelerates DNA damage and other senescence-inducing stresses. Moreover, immune dysfunction during aging impairs the clearance of senescent cells, allowing them to accumulate and persist. This persistence prolongs SASP activity, which further fuels local and systemic inflammaging. Together, these processes form a self-reinforcing positive feedback loop, in which SASP amplifies inflammaging, whereas inflammaging sustains and exacerbates SASP activity. Over time, this loop magnifies tissue damage, exhausts regenerative capacity, and creates a permissive environment for age-related pathologies. Context-dependent effects of SASP and inflammaging Not all SASP profiles are created equal because their composition varies significantly depending on cell type, senescence-inducing stimulus, and the surrounding microenvironment, ultimately affecting its inflammatory potential and biological outcomes54. While many senescent cells secrete a core group of SASP components such as IL-6, IL-8 and MMPs, their abundance, combination, and downstream effects differ by tissue and senescence context7,54. For instance, oncogene-induced senescence differs from DNA damage- or replicative-induced senescence in secretome composition7,15. A notable case is mitochondrial dysfunction-associated senescence (MiDAS), which lacks key inflammatory cytokines such as IL-1α and IL-1β, yet produces other components like growth differentiation factor 15 (GDF15) and specific proteases7,46. Thus, the inflammatory signaling of senescent cells is not uniform but varies by intracellular triggers and damage type54. Cellular source specificity The biological outcomes of SASP are profoundly influenced by the originating cell type. Specifically, senescent fibroblasts typically secrete IL-6, IL-8, and MMPs, promoting epithelial proliferation, cancer cell invasion, and angiogenesis14,55. However, they may also stimulate immune clearance in early-stage tumors8,53,56. Senescent mesenchymal stem cells (MSCs) produce components that affect regeneration and immune modulation20. Senescent glial cells contribute to neuroinflammation by promoting tau aggregation and inflammasome activation, driving neurodegeneration and cognitive decline57. Senescent endothelial cells release SASP rich in adhesion molecules, angiogenic factors, and TGF-β family members, leading to inflammation, fibrosis, vascular remodeling, and paracrine endothelial dysfunction, all of which disrupt vascular barriers and promote sclerosis58. Senescent keratinocytes secrete high levels of MMPs, IL-8, and chemokines, contributing to local matrix degradation and neutrophil recruitment, eventually causing chronic skin inflammation and pigmentation disorders. Senescent chondrocytes predominantly release catabolic enzymes such as MMP-13 and ADAMTS, along with inflammatory cytokines like IL-1β, which drive cartilage destruction and interact with synovial macrophages to form inflammatory feedback loops that exacerbate osteoarthritis31,59,60. Senescent hepatocytes secrete IL-6 with potential anti-tumor effects, highlighting organ-specific roles61,62. Tissue/Organ specificity SASP-driven inflammaging does not act uniformly across the body but instead manifests in a tissue- and organ-specific manner, reflecting differences in cellular sources, microenvironmental cues, and signaling pathways54. Accumulating evidence shows that SASP induces distinct patterns of chronic inflammation and functional decline across skeletal, vascular, neural, metabolic, hepatic, renal, and cutaneous systems. In joints and skeletal tissues, senescent chondrocytes and osteocytes release pro-inflammatory cytokines like IL-1β and IL-6 and proteases MMP-13, accelerating cartilage and bone matrix breakdown60. These changes underlie osteoarthritis pain and osteoporosis progression by both degrading tissue architecture and sensitizing nociceptors63. In the cardiovascular system, endothelial and smooth muscle cells secrete SASP factors like IL-6, TNF-α, adhesion molecules, and proteases, promoting leukocyte recruitment, vascular remodeling, and atherosclerotic plaque instability64. In the nervous system, senescent astrocytes and microglia generate a SASP characterized by IL-1β, IL-6, and TNF-α. In this context, SASP factors interact with neuronal signaling and blood–brain barrier integrity, contributing to a neuroinflammatory microenvironment that drives synaptic dysfunction and cognitive decline65. In metabolic tissues, senescent preadipocytes and adipocytes release IL-6, IL-1β, and MCP-1, inducing metaflammation, insulin resistance, and cardiovascular risk66–68, while hepatic and renal senescent cells secrete TGF-β and IL-6, driving fibrosis and organ dysfunction. In the skin, senescent fibroblasts and keratinocytes secrete IL-8 and MMPs that degrade extracellular matrix and alter the stem cell niche69. Overall, SASP consistently promotes inflammaging, but its pathological outcomes are organ-specific, ranging from joint degeneration and vascular disease to neurodegeneration and fibrosis. Although all are SASP-driven, they represent divergent pathological outcomes due to differences in SASP profiles and tissue targets, highlighting the need for tissue-tailored therapeutic strategies. Time and disease stage dependency SASP’s biological effects are dynamic and largely depend on timing and disease stage. Early in stress responses or acute injury, SASP may serve beneficial functions. For example, transiently senescent keratinocytes and fibroblasts produce PDGF and VEGF to support angiogenesis and regeneration in skin wound healing19,20. These cells are subsequently cleared by apoptosis or immune mechanisms, restoring SASP to baseline and preventing chronic inflammation7. Similarly, in liver injury or bone fracture, short-term SASP promotes stem cell activation and tissue remodeling20,70. However, failure to eliminate senescent cells results in persistent SASP, creating a pro-inflammatory microenvironment that drives chronic inflammation, immune exhaustion, and bystander senescence16,71. In aging skin, persistent SASP from keratinocytes and fibroblasts leads to chronic wounds, elastin degradation, fibrosis, and possibly pre-cancerous changes71. SASP also exhibits biphasic effects in cancer. During early tumorigenesis, SASP can activate anti-tumor immunity and induce tumor cell senescence or apoptosis via IL-6 and IL-1α signaling8,53. In contrast, at later stages, SASP promotes immunosuppressive cell recruitment, such as regulatory T cells (Tregs) and tumor-associated macrophages (TAMs), thereby facilitating tumor immune evasion and enhancing invasiveness23. Similarly, therapy-induced SASP may initially inhibit tumor growth, but later support relapse and resistance if senescent tumor cells persist72. Microenvironmental dependencies The impact of SASP is highly context-dependent, shaped by the local cellular milieu and extracellular matrix (ECM). In fibrotic niches, TGF-β-rich SASP promotes collagen deposition and tissue stiffening, linking senescence to fibrosis in organs like the lungs, kidneys, and heart73. In obese or aged adipose tissue, chemokine-rich SASP attracts and activates macrophages, sustaining local inflammation and elevating systemic IL-6 and CRP levels74. Conversely, a youthful microenvironment can counteract the detrimental effects of SASP, restoring tissue homeostasis via anti-inflammatory cues and efficient immune clearance. Tissue context also governs how deleterious SASP-driven inflammation will be. Some tissues can better tolerate or even exploit a transient SASP. In the central nervous system (CNS), even low levels of SASP from senescent glia can spark neuroinflammatory cascades due to immune privilege, resulting in synaptic injury, tauopathy, and cognitive decline26. In contrast, senescent fibroblasts in muscle are often efficiently cleared by resident macrophages, preventing sustained inflammation. The regenerative capacity of an organ also determines its resilience to SASP. Organs like the liver, with high regenerative potential, may repair SASP-induced damage, whereas tissues like cartilage or neurons, with low regenerative ability, accumulate irreversible damage18,75. This underscores the divergent roles of SASP across tissues, timeframes, and disease contexts. Mechanistic basis for context-dependency Heterogeneous triggers of cellular senescence Cellular senescence is a stress-induced state of irreversible cell cycle arrest, originally identified in replicative fibroblast models76,77. Decades later, Harley demonstrated that DNA replication-induced telomere damage could trigger senescence, now referred to as replicative senescence78. Subsequent studies demonstrated that oncogene overexpression, such as RAS, activates a DNA damage-like response in primary cells, leading to oncogene-induced senescence (OIS)79,80. In addition, senescence can be triggered by a variety of stress signals, including DNA damage3, radiotherapy or chemotherapy21,31, oxidative stress (excess ROS), cytokine treatments, malnutrition or metabolic dysfunction46, mitochondrial dysfunction81, and reprogramming to induced pluripotent stem cells (iPSCs)82. Among these, DNA double-strand breaks in cancer and precancerous cells represent a frequent cause of senescence during cancer treatment, known as therapy-induced senescence (TIS)83. These heterogeneous triggers result in different SASP compositions and dynamics, explaining why SASP may act as a regenerative signal in acute injury but drive chronic inflammation under persistent stress (Fig. 3). Heterogeneous triggers of cellular senescence. Cellular senescence can be induced by diverse intrinsic and extrinsic stimuli. Intrinsic triggers include DNA damage, telomere shortening, oxidative stress, mitochondrial dysfunction, oncogene activation, and epigenetic alterations. Extrinsic triggers encompass radiation, chemotherapy, cytokine exposure, metabolic stress, and cellular reprogramming. These heterogeneous stimuli lead to distinct senescent phenotypes and variable SASP compositions, explaining the context-dependent effects of senescence that may be beneficial in acute injury repair but detrimental when persistent. (Created in BioRender. liu, Q. (2026) https://BioRender.com/5mi1v5b). Diverse cellular sources of SASP in aging Senescent cells accumulate in multiple tissues with age, providing widespread sources of SASP in the elderly30,84. Virtually all cell types can undergo senescence, including stromal, immune, epithelial, and tissue-specific populations, resulting in diverse cellular sources of SASP during aging85. Although the composition of SASP varies depending on cell type and context, most senescent cells secrete pro-inflammatory cytokines, chemokines, proteases, and growth factors that converge on similar outcomes, including chronic inflammation, tissue remodeling, and impaired regeneration. Representative cellular sources and their characteristic SASP profiles are summarized in Table 2 and Fig. 4. Table 2Diverse cellular sources of SASP and their characteristic secretory profilesCell TypeRepresentative SASP FactorsKey Functional ConsequenceRef.FibroblastsIL-6, IL-8, MMPsECM degradation, chronic inflammation, epithelial transformation, and tumorigenesis55,69,172Epithelial CellsIL-6, TGF-β, MMPsFibrosis, inflammation, organ dysfunction, and immune modulation137Endothelial and Smooth Muscle CellIL-1β, IL-6, TNF-α, MMP12/13, adhesion moleculesVascular inflammation, leukocyte recruitment, plaque instability, atherosclerosis progression124,173Preadipocytes and AdipocytesIL-6, IL-1β, MCP-1Metaflammation, insulin resistance, systemic metabolic dysfunction66,67,105,174Immune Cells (T cells, macrophages, NK cells)IL-6, TNF-α, chemokinesImmunosenescence, impaired immune surveillance, amplification of chronic inflammation16,175–177Stromal and Stem CellsIL-6, chemokines, growth factorsImpaired regeneration, stem cell exhaustion, disruption of tissue homeostasis178Glial Cells (astrocytes, microglia)IL-1β, IL-6, TNF-αNeuroinflammation, neuronal dysfunction, neurodegeneration26,57,179,180Skeletal Cells (osteoblasts, osteocytes, chondrocytes)IL-6, IL-1β, TNF-α, MMP-13Bone remodeling imbalance, cartilage degradation, osteoarthritis progression181Tumor CellsIL-6, IL-8, MMPs, growth factorsTumor microenvironment remodeling, immune modulation, therapy resistance and recurrence182SASP Senescence-Associated Secretory Phenotype, ECM Extracellular Matrix. Diverse cellular sources of SASP and their characteristic secretory profiles SASP Senescence-Associated Secretory Phenotype, ECM Extracellular Matrix. Diverse cellular sources of SASP in aging and their pathological outcomes. Senescent cells arise from multiple cellular origins during aging, including fibroblasts, epithelial cells, endothelial and smooth muscle cells, adipocytes, immune cells, stromal and stem cells, glial cells, tumor cells, and bone-related cells (osteoblasts, osteocytes, and chondrocytes). Each source produces a distinct SASP profile, shaping tissue-specific microenvironments and driving diverse pathological outcomes. For example, senescent fibroblasts promote extracellular matrix remodeling and tumor progression; senescent endothelial and smooth muscle cells contribute to vascular inflammation and atherosclerosis; adipocyte-derived SASP induces metabolic dysfunction and obesity-associated inflammation; senescent glial cells fuel neuroinflammation and neurodegeneration; and senescent chondrocytes accelerate osteoarthritis and osteoporosis. Collectively, these heterogeneous cellular sources of SASP underpin the tissue- and disease-specific manifestations of inflammaging, thereby linking cellular senescence to a broad spectrum of age-related disorders. (Created in BioRender. liu, Q. (2026) https://BioRender.com/971lqj7). Distinct molecular pathways governing SASP output Beyond triggers and cellular sources, SASP is shaped by multiple regulatory networks that determine its composition and persistence (Fig. 5). Distinct molecular pathways regulating SASP production. Multiple signaling pathways orchestrate the induction and regulation of the SASP, contributing to its context-dependent nature. DNA damage response (DDR) activates p53 and p21, leading to cell cycle arrest and SASP initiation. NF-κB serves as a central transcriptional regulator of SASP components. mTOR signaling modulates IL-1α translation and reinforces NF-κB activity. cGAS–STING senses cytoplasmic DNA fragments and induces type I interferons, IL-6, and TNF. NLRP3 inflammasome activation promotes IL-1β and IL-18 secretion. p38 MAPK amplifies NF-κB-mediated SASP gene expression. JAK/STAT signaling, activated by IL-6, further drives pro-inflammatory and pro-senescent gene programs. PI3K/AKT promotes mTORC1-dependent SASP induction. Together, these interconnected pathways govern cell cycle arrest, senescence establishment, and SASP output, underpinning the heterogeneity and context-dependency of SASP in aging and disease. (Created in BioRender. liu, Q. (2026) https://BioRender.com/n5jymrq). DNA damage response (DDR) and p53/p16 independence Persistent DDR is a primary trigger of both cellular senescence and SASP, initiating their activation in response to genomic stress. Damage from telomere attrition, oxidative stress, or oncogene activation stimulates ATM/ATR kinases, which in turn activate tumor suppressor pathways such as p53 and p16INK4a, leading to cell cycle arrest and driving SASP production3. Interestingly, although p53 and p16 are canonical mediators of growth arrest, SASP can still be generated even in the absence or inhibition of p53 and p16INK4a, indicating the existence of alternative regulatory mechanisms3,86. Studies have shown that p53-deficient cells are still capable of producing SASP, implying that distinct branches of the DDR independently control SASP expression3. One such pathway involves the transcriptional regulator GATA4. Upon activation of DDR, the autophagic degradation of GATA4 is inhibited, leading to its accumulation in senescent cells3,87. GATA4 then acts via intermediate adaptors such as TRAF3IP2 to initiate a cascade that activates NF-κB and induces the transcription of SASP-related genes3,88. Notably, this pathway operates independently of p53 status, indicating that while p53 may mediate cell cycle arrest, the GATA4/NF-κB axis can autonomously trigger the inflammatory SASP response. NF-κB and transcriptional regulation of SASP As a master regulator of inflammatory gene expression, NF-κB plays a central role in the induction of the SASP27. In senescent cells, NF-κB is typically in a constitutively active state and is responsible for driving the transcription of numerous SASP components, such as IL-6, IL-8, and TNF-α89. Multiple pathways converge to activate NF-κB during cellular senescence. One key upstream signal originates from the DDR, which activates NF-κB through the ATM–IκB kinase axis90,91. In addition, a cytokine-mediated positive feedback loop, particularly through IL-1α, further sustains NF-κB activity. IL-1α is upregulated early in the senescence process and remains tethered to the plasma membrane of senescent cells, where it acts in an autocrine fashion to stimulate the IL-1 receptor and maintain NF-κB signaling33,92. Accordingly, blockade of IL-1α or its receptor significantly reduces NF-κB activity and dampens SASP secretion in senescent cells37,92. mTOR pathway and translation of SASP components mTOR, as a central regulator of nutrient sensing and cellular growth and the mechanistic target of rapamycin, plays a pivotal role in modulating SASP expression. While best known for regulating protein synthesis and metabolism, mTOR in senescent cells specifically enhances the translation of certain SASP mRNAs93. A prominent example is IL1A, where mTOR activity increases the translation efficiency of IL1A mRNA, ensuring robust expression of this key SASP-inducing cytokine and thereby amplifying the overall SASP response37,93. Pharmacological inhibition of mTOR using rapamycin or its analogs significantly reduces SASP expression while maintaining growth arrest in senescent cells. Previous studies have demonstrated that rapamycin treatment suppresses IL-1α translation and downstream NF-κB activity, leading to a marked attenuation of the pro-inflammatory SASP gene signature37,93,94. Importantly, this process forms a positive feedback loop. Briefly, IL-1α activates NF-κB, which in turn induces further IL-1α production and mTOR sustains this loop by maintaining a high supply of IL-1α protein37,93. Innate immune DNA-sensing (cGAS–STING) pathway Senescent cells often exhibit chromatin alterations, including the leakage of DNA fragments into the cytoplasm. These cytosolic DNA fragments activate cyclic GMP-AMP synthase (cGAS), which in turn activates the stimulator of interferon genes (STING) pathway, a component of the innate immune system that normally senses viral DNA95,96. During senescence, cGAS binds cytoplasmic chromatin fragments and catalyzes the production of cyclic GMP-AMP (cGAMP), which activates STING. STING signaling then induces a subset of SASP factors, particularly type I interferons and associated inflammatory mediators95–98. This pathway has been identified as a central regulator of SASP. In short, cells deficient in cGAS or STING exhibit a markedly attenuated SASP response to DNA damage96,99,100. Through STING signaling, senescent cells simultaneously activate the transcription factors NF-κB and IRF3, enhancing both interferon-inducible SASP components and paracrine transmission of the senescence phenotype to neighboring cells96,100,101. This mechanism links genomic instability to chronic inflammation, both of which are hallmarks of aging. NLRP3 inflammasome and IL-1β activation The NLRP3 inflammasome, another critical arm of innate immune signaling, has emerged as an important contributor to senescence-associated inflammation and SASP activity. This multi-protein complex, predominantly formed in immune cells like macrophages, promotes the maturation of IL-1β and IL-18 upon activation102,103. Previous studies suggest that SASP components can provide both the priming and activating signals for NLRP3. Mechanistically, senescent cells release ATP, reactive oxygen species (ROS), and DAMPs, all of which are capable of triggering NLRP3 activation in macrophages33. Meanwhile, SASP cytokines such as TNF-α and IL-6 enhance pro-IL-1β expression during the priming phase102,103. MAPK p38 Pathway The MAPK p38 pathway is frequently activated in senescent cells and serves as an important upstream regulator of SASP gene transcription, enhancing the expression of various SASP components. For instance, p38 MAPK drives IL‑6 and IL‑8 expression in senescent fibroblasts, and inhibition of p38 significantly reduces these SASP factors38. Additionally, p38 enhances NF‑κB activity to maintain SASP expression and stability, thus emphasizing its critical role as an upstream node of SASP regulation27. Recent studies have also demonstrated that p38 MAPK/NF‑κB signaling is activated in oxidative stress-induced endothelial senescence, and pharmacological inhibition of p38 alleviates this inflammatory aging phenotype104. JAK/STAT signaling pathway The JAK/STAT pathway operates downstream of SASP cytokines such as IL-6, signaling through JAK/STAT3 to potentially induce pro-inflammatory and pro-senescent gene expression in neighboring cells32,33. Chronic IL-6/STAT3 signaling can promote inflammatory paracrine senescence within the tissue microenvironment32. In vivo studies have confirmed that JAK1/2 inhibitors like ruxolitinib markedly reduce SASP expression, particularly IL‑6, thereby ameliorating systemic inflammation and improving physical function in aged mice105,106. Similarly, inhibition of the JAK/STAT pathway in tendon stem cells leads to reduced expression of p16 and inflammatory cytokines such as IL‑6 and IL‑1β, thereby alleviating senescence107. The IL‑6–STAT3 axis is increasingly recognized as a central mechanism in the amplification of paracrine SASP signaling32,108. PI3K/AKT pathway and autophagy The PI3K/AKT signaling pathway interacts with SASP via mTOR and regulates SASP through modulation of autophagy109. Activation of PI3K/AKT stimulates mTORC1, promoting the translation and secretion of specific SASP factors such as IL‑6 and IL‑1α110. Meanwhile, mTOR activity suppresses autophagy, leading to cytoplasmic damage accumulation and enhanced SASP production93,109. Conversely, active autophagy can suppress SASP secretion by removing harmful cytoplasmic components111. Summary Collectively, SASP production and its associated inflammatory effects are governed by a complex and interconnected regulatory network. These pathways integrate diverse stress signals to initiate and sustain SASP expression, linking cellular damage to chronic inflammation and tissue dysfunction. In addition, SASP output is further shaped by multiple regulatory processes, including redox control mediated by NRF2112–114, epigenetic remodeling that alters chromatin accessibility115–117, post-transcriptional regulation by non-coding RNAs118, and transcriptional repression mechanisms involving Polycomb group proteins119. Together, these layers of regulation contribute to the dynamic and context-dependent nature of the SASP, providing a mechanistic basis for its diverse roles in aging and age-related diseases. SASP and inflammaging in aging and age-related diseases Studies have shown that the burden of senescent cells increases throughout life and is detectable in multiple organs of elderly humans and rodents8,11. These cells are particularly enriched in tissues exposed to chronic stress or active regeneration, such as the skin, adipose tissue, bone marrow, liver, kidney, lung, and the cardiovascular system8,10,84. Notably, senescent cells often appear at sites of age-related pathology, implying their involvement in disease progression10. For example, p16INK4a+ senescent cells have been observed in arthritic joints, atherosclerotic plaques, osteoporotic bone, and aging brain tissue, all of which are regions typically associated with chronic inflammatory diseases10,120,121 (Fig. 4). Osteoarthritis and osteoporosis In joint tissues, SASP-driven activation of NF-κB and inflammasomes contributes to chronic synovitis and cartilage degradation, ultimately triggering osteoarthritis59. Specifically, within aging and post-traumatic joints, senescent chondrocytes, synovial fibroblasts, and osteocytes secrete inflammatory SASP factors such as IL-1β, IL-6, IL-8 and MMP-13, which drive cartilage degradation, joint inflammation, and bone remodeling defects, thereby contributing to disease progression59. These SASP factors not only degrade the extracellular matrix but also induce secondary senescence in nearby cells and promote osteoclast activation, ultimately aggravating osteoporosis and structural deterioration59. Moreover, SASP accumulation in the joint microenvironment sensitizes nociceptors, contributing to pain, and the spillover of inflammatory mediators may elicit systemic inflammaging59,122. Preclinical models show that senescent cell accumulation accelerates cartilage loss, bone resorption and muscle wasting, whereas senescent cell clearance alleviates inflammation and pain, confirming the causal role of SASP and inflammaging in that context60. Atherosclerosis and cardiovascular diseases In the cardiovascular system, for instance, SASP factors secreted by senescent endothelial cells promote endothelial dysfunction and hypertension, while SASP from senescent foam cells accelerates plaque development, collectively increasing the risk of myocardial infarction and stroke58. Specifically, in atherosclerotic plaques, senescent foam cell macrophages and endothelial cells secrete a SASP enriched in pro-inflammatory cytokines such as IL-1α, IL-1β, IL-6 and TNF-α, along with chemokines, proteases, and adhesion molecules like VCAM-158. Within the arterial wall, these factors perpetuate monocyte and leukocyte recruitment, impair endothelial function, and drive vascular remodeling121. Protease-mediated degradation of the fibrous cap weakens plaque stability, increasing the risk of rupture64. Systemically, SASP-associated cytokines contribute to endothelial dysfunction and metabolic disturbances, including insulin resistance123. Animal studies show that clearance of vascular senescent cells or inhibition of SASP pathways reduces vascular inflammation and atherogenesis, and lowers circulating inflammatory cytokines121,124. Clinical studies have shown that elevated circulating IL-6 and TNF-α levels in older adults are strongly associated with increased cardiovascular mortality, supporting the concept that SASP-driven inflammaging accelerates vascular pathology121,125. Neurodegenerative diseases In the central nervous system, chronic SASP activity in astrocytes and microglia is a key driver of neuroinflammation and neuronal dysfunction. Persistent activation of NF-κB orchestrates the SASP transcriptional program in glial cells by integrating diverse upstream signals, including DNA damage, cytokine signaling, and Toll-like receptor engagement by DAMPs13. A reinforcing loop exists between SASP and NLRP3 inflammasome activation. SASP triggers inflammasome activity, while the resulting IL-1β and IL-18 further enhance SASP expression or promote additional senescence33,103. Senescent cells themselves may harbor active NLRP3 inflammasomes, contributing directly to IL-1β production126,127. This feedback exacerbates tau hyperphosphorylation, protein aggregation, and neuronal death, all hallmarks of Alzheimer’s pathology128. Consistently, NLRP3 activation and elevated IL-1β levels are observed in aged individuals, and NLRP3-deficient mice exhibit improved insulin sensitivity and reduced cognitive decline, underscoring the pathogenic role of SASP-inflammasome crosstalk in neurodegenerative disease and inflammaging progression129–132. Metabolic disorders and fibrosis Senescent adipocytes and preadipocytes produce a SASP enriched in IL-6, IL-1β and MCP-1 that drives systemic metaflammation, insulin resistance and metabolic dysfunction, which plays a central role in the pathogenesis of age-related metabolic diseases, including obesity, type 2 diabetes, and cardiovascular disease66–68. In metabolic organs such as the liver, kidney and lung, senescent epithelial cells and stellate or myofibroblast populations secrete TGF-β and other pro-fibrotic mediators that recruit and activate fibroblasts and immune cells, thereby promoting extracellular matrix deposition and progressive fibrosis133,134. Preclinical studies demonstrate that genetic or pharmacological ablation of senescent cells, or inhibition of SASP and inflammasome signaling, ameliorates insulin resistance and alleviates fibrotic remodeling, underscoring the pathological role of chronic SASP in metabolic tissues66,71,105. Beyond metabolic dysfunction, SASP factors also govern the balance between regeneration and fibrosis in a context-dependent manner. In tissues with high regenerative ability, such as the liver and muscle, a transient SASP following acute injury can promote repair by stimulating progenitor cell proliferation and recruiting immune cells that facilitate clearance of damaged cells20. Conversely, in chronically damaged or aged tissues, persistent SASP from senescent hepatic stellate cells or fibroblasts drives excessive extracellular matrix deposition, pathological scarring, and impaired regeneration135. In contrast, in organs with low regenerative ability like the lung, senescent epithelial cells and myofibroblasts secrete pro-fibrotic mediators such as TGF-β and MMPs, which perpetuate collagen accumulation, disrupt architecture, and suppress tissue repair capacity71,136,137. These observations underscore that SASP can act as a double-edged sword, being acutely beneficial in tissue recovery but chronically pathogenic by locking tissues into a fibrotic, non-regenerative state. Cancer and therapy-induced senescence In the tumor microenvironment, SASP exerts context-dependent effects on tumorigenesis. Senescent stromal cells, particularly fibroblasts, secrete a complex SASP enriched in IL-6, IL-8, and MMPs, which remodel the extracellular matrix, stimulate angiogenesis, and support tumor cell proliferation and invasion36. At the same time, SASP chemokines such as CXCL1 and CCL2 can enhance anti-tumor immunity by recruiting cytotoxic immune cells to eliminate premalignant cells138,139. This duality highlights the temporospatial dependence of SASP that transient SASP in early tumorigenesis may contribute to immune-mediated clearance, whereas chronic SASP in aged tissues or established tumors fosters genomic instability, immune evasion, and therapy resistance8,21,53. In this context, the balance typically shifts toward tumor promotion, as chronic inflammation and DNA damage create a permissive niche for malignant progression53. Experimental and translational data indicate that modulating SASP or removing therapy-induced senescent cells can reduce tumor-promoting effects of the microenvironment72,139. Thus, SASP represents both a tumor-suppressive barrier and a tumor-promoting driver, with outcomes determined by cellular context and tissue microenvironment. Summary Collectively, evidence from diverse organ systems demonstrates that SASP and inflammaging constitute a unifying mechanism linking cellular senescence to age-related pathologies. These heterogeneous outcomes mentioned above are orchestrated by conserved signaling networks, including NF-κB, mTOR, DDR pathways, and innate immune sensors such as cGAS–STING and NLRP3 inflammasomes, which not only govern the initiation and amplification of SASP responses, but are also intimately involved in the pathogenesis of various age-related diseases, highlighting the intrinsic link between SASP biology and age-associated pathology (Table 3). Table 3Pathways Linking SASP to DiseasesDisease TypeSASP-Associated MechanismRef.Osteoporosis and OsteoarthritisSASP disrupts bone homeostasis by promoting osteoblast senescence and enhancing osteoclast activity151Tumorigenesis and RecurrenceSASP facilitates tumor immune evasion and reshapes the tumor microenvironment21,24,183Neurodegenerative DiseasesSASP induces glial inflammation and contributes to neuronal death144Pulmonary, Hepatic, and Renal FibrosisSASP activates immune cells and fibroblasts, promoting chronic tissue fibrosis71Cardiovascular DiseasesSASP exacerbates vascular inflammation, cardiomyocyte apoptosis, and inflammatory cardiac aging12,184Immunosenescence and InflammagingSASP reshapes immune cell lineages and sustains chronic low-grade inflammation that drives disease progression13,16SASP Senescence-Associated Secretory Phenotype. Pathways Linking SASP to Diseases SASP Senescence-Associated Secretory Phenotype. For example, chronic activation of NF-κB has been observed in sarcopenia, osteoarthritis, and Alzheimer’s disease140,141; overactivation of mTOR signaling has been implicated in metabolic syndrome, certain cancers, immunosenescence, type 2 diabetes and Alzheimer’s disease142; excessive stimulation of the STING pathway may lead to autoimmune-like inflammation during aging, as some inflammaging phenotypes mirror interferon-driven diseases143,144; and activation of the NLRP3 inflammasome has been associated with the progression of atherosclerosis, type 2 diabetes, and neurodegenerative disorders145,146. Through the induction of SASP, these pathways create a pro-inflammatory tissue microenvironment that lowers the threshold for disease onset and progression. Importantly, despite this heterogeneity, a unifying principle emerges that reducing senescent cell burden or modulating SASP activity consistently confers benefits across tissues, underscoring chronic SASP as a common driver of age-related pathology and a promising therapeutic target147. Therapeutic strategies targeting SASP and inflammaging Given the pervasive role of SASP and inflammaging in driving pathology across multiple organ systems, targeting senescent cells and their secretory programs has emerged as a compelling therapeutic strategy. Preclinical and clinical studies suggest that interventions aimed at reducing senescent cell burden (senolytics) or modulating SASP activity (senomorphics) can alleviate tissue dysfunction, delay disease progression, and potentially extend healthspan. Moreover, insights into the core signaling pathways underlying SASP regulation such as NF-κB, mTOR, cGAS–STING, and NLRP3, have revealed actionable molecular targets that may allow more selective and context-dependent interventions. These advances highlight a growing translational potential, positioning senescence-targeted therapies at the forefront of strategies to mitigate age-related diseases and improve late-life health outcomes. Senolytics Senolytics, such as navitoclax or the dasatinib-quercetin combination, selectively eliminate senescent cells and remove the source of SASP148. In animal models, senolytics restore tissue function, reduce chronic inflammation, and extend both healthspan and lifespan10,149,150. For instance, eliminating senescent cells in progeroid mice delays phenotypes such as cataracts, muscle wasting, and thymic atrophy10,34. In naturally aging mice, periodic senolytic treatment mitigates degenerative changes across multiple organs and reduces systemic levels of inflammatory factors like IL-6 and TNF-α, further supporting their role in mitigating systemic inflammaging147,149. Beyond aging models, senolytics show efficacy in diverse pathological settings. In cardiovascular disease, clearance of senescent endothelial cells improves vascular reactivity and attenuates atherosclerosis development104,149. In musculoskeletal disorders, senolytic treatment alleviates joint inflammation and cartilage degeneration in osteoarthritis models147. In metabolic disease, removal of senescent adipocyte progenitors improves insulin sensitivity and glucose homeostasis16,151. In the nervous system, experimental senolytic interventions reduce neuroinflammation and improve cognitive function in mouse models of Alzheimer’s disease and tauopathy, suggesting a potential role in delaying neurodegenerative processes57. These findings highlight the broad therapeutic potential of senolytics across age-related pathologies. Importantly, early-phase clinical trials are beginning to validate these preclinical observations. The D + Q combination has shown promise in improving physical function and reducing senescence-associated biomarkers in patients with idiopathic pulmonary fibrosis and diabetic kidney disease148,152. In the context of neurodegeneration, fisetin, a naturally occurring flavonoid with senolytic activity, has entered clinical testing for Alzheimer’s disease and related dementias, based on preclinical evidence of reduced glial senescence and improved cognitive performance26,153. Together, these studies highlight the translational potential of senolytics across multiple age-related conditions, including cardiovascular, metabolic, and neurodegenerative diseases. Despite these advances, challenges remain. Navitoclax, while effective, causes dose-limiting thrombocytopenia due to BCL-XL inhibition in platelets, underscoring the need for more selective agents with reduced toxicity154. Additionally, senescent cells are heterogeneous across tissues, and broad clearance strategies may carry risks, such as impairing wound healing or tissue repair where transient senescence is beneficial. Besides, current senolytics may exhibit off-target effects. Efforts are underway to improve targeted drug delivery based on senescent cell-specific features like elevated β-galactosidase activity, dependence on anti-apoptotic proteins, or unique surface markers84,155. Senomorphics Senomorphics represent an alternative strategy to senolytics by suppressing inflammatory factor secretion without eliminating the senescent cells themselves. This approach aims to preserve the potentially beneficial roles of senescent cells, such as structural support and tissue repair, while minimizing their harmful paracrine effects. Rapamycin, an mTOR inhibitor, and metformin, an AMPK activator, have been shown to suppress SASP production112,156. Rapamycin inhibits the translation of IL-1α and activation of NF-κB in senescent cells, persistently reducing SASP output and extending lifespan in all tested species, aligning with the goal of mitigating inflammaging93,157. Similarly, metformin functions by restraining SASP output through AMPK-mediated inhibition of inflammatory signaling, particularly NF-κB activity, while also reducing oxidative and metabolic stress associated with inflammaging156. JAK inhibitors like ruxolitinib reduce SASP activity by blocking downstream IL-6/IL-8 signaling106. In animal studies, such agents re-establish tissue homeostasis by lowering systemic inflammation10,105. Similarly, targeting the NLRP3 inflammasome, for example with MCC950, also holds promise, significantly reducing IL-1β levels and markers of senescence in aged mouse tissues129,158,159. In fact, rapamycin treatment, for instance, has been shown to reduce SASP expression and improve inflammation-associated aging phenotypes. In clinical studies, topical rapamycin application significantly decreased the proportion of p16INK4a positive senescent cells in aged human skin, correlating with improved skin inflammation and aging markers93,160. These senomorphics approaches may offer unique advantages in scenarios where senescent cells provide beneficial effects, such as in wound healing or tumor suppression161. Emerging strategies now focus on temporally controlled SASP modulation to achieve therapeutic benefits while minimizing potential drawbacks of chronic suppression. Immunomodulatory approaches With advancing age, immune surveillance against senescent cells becomes impaired, a phenomenon known as immunosenescence, which contributes to the persistence of senescent cells and the progression of age-related diseases16. Restoring or enhancing immune-mediated clearance is therefore an attractive therapeutic strategy7. Recent studies have demonstrated the potential of adoptive cellular immunotherapies to directly eliminate senescent cells. Chimeric antigen receptor (CAR) T cell-based approaches targeting senescence-associated surface markers have shown promising results in preclinical models133,162. Senolytic CAR T cells selectively remove senescent cells and produce durable improvements in metabolic function and age-associated phenotypes150. For example, uPAR-targeted CAR-T cells improved exercise capacity and metabolic function in aged mice after a single administration, while NKG2D-CAR-T cells selectively eliminated senescent cells in aged mice and nonhuman primates without observed adverse effects162–164. Moreover, strategies to rejuvenate innate immune cells, such as NK cells and macrophages, are under investigation, given their central role in eliminating senescent cells but declining functionality with age16,165. Targeting inflammatory pathways linked to immune dysfunction has shown clinical relevance. IL-1β inhibition with canakinumab, as demonstrated in the CANTOS trial, reduced cardiovascular events and cancer incidence in patients with atherosclerosis166,167. Similarly, NLRP3 inhibitors like MCC950 suppressed IL-1β release and alleviated vascular and metabolic dysfunction129,158. Overall, immunomodulatory approaches, including CAR T cells, vaccines, antibodies, and inflammasome inhibitors, offer complementary strategies to pharmacological senolytics and senomorphics, aiming to restore immune control over senescent cells and mitigate SASP-driven inflammaging7,149. Targeted delivery systems A major limitation of current senolytics and senomorphics lies in their off-target effects and systemic toxicity. To address these challenges, targeted delivery systems are being developed to enhance drug specificity for senescent cells while minimizing adverse effects7,149. One promising strategy is the use of galacto-conjugated prodrugs, which exploit the elevated β-galactosidase activity of senescent cells155. For example, galacto-conjugated navitoclax demonstrated selective senolytic activity while sparing platelets, significantly reducing toxicity in preclinical models154. Similarly, nanoparticle-based carriers and antibody-drug conjugates can be engineered to recognize senescence-associated surface antigens, thereby improving targeted drug delivery7,163. In addition, nanotechnology and biomaterials provide versatile platforms for controlled release. Nanoparticles functionalized with senescence-specific ligands allow selective accumulation in senescent tissues, while biodegradable polymers enable localized and sustained release of senolytics or senomorphics agents7,161. These strategies not only increase therapeutic efficacy but also reduce systemic exposure. Emerging approaches also include cell- and gene-based delivery systems, such as viral vectors or engineered immune cells, designed to deliver senescence-modulating molecules directly into target tissues133,150. Such methods offer the possibility of precise, context-dependent modulation of SASP without broadly affecting non-senescent cells. Collectively, targeted delivery strategies represent a crucial step toward the clinical translation of senescence-based therapies. By improving selectivity and safety, these approaches may overcome the key limitations of current senolytics and senomorphics, enabling their application across a broader spectrum of age-related diseases. Conclusion and future perspectives As populations worldwide continue to age, the burden of chronic, age-related diseases has become an urgent global challenge. Cellular senescence and SASP have emerged as central players in the aging process, primarily by initiating pro-inflammatory states that compromise tissue function. Persistent SASP activity fuels inflammaging, creating a self-reinforcing cycle that accelerates the onset and progression of diseases across multiple organ systems, including cardiovascular, musculoskeletal, neurodegenerative, metabolic, and malignant disorders. SASP provides a unifying framework to explain both the chronic low-grade inflammation associated with aging and its role in promoting age-related diseases. Current evidence supports a model in which senescent cells are initially protective against damage or cancer, and then accumulate in aged tissues like Trojan horses, ultimately releasing chronic SASP that the body cannot efficiently resolve. This persistent SASP contributes to pathological alterations such as stem cell niche dysfunction, impaired tissue repair, fibrosis or atrophy, and immune dysregulation, collectively leading to frailty, disability, and disease in the elderly. A critical insight is that inflammaging is not merely a byproduct of aging but an active mediator of it. SASP-driven inflammaging accelerates the pathology of nearly all organ systems, revealing a promising therapeutic opportunity, as targeting SASP or senescent cells may serve as a multipurpose strategy against various age-related diseases. Growing insights into the regulatory networks underlying SASP, such as NF-κB, mTOR, cGAS–STING, and NLRP3, have revealed potential therapeutic targets. Emerging interventions, ranging from senolytics and senomorphics to immunomodulatory and targeted delivery strategies, demonstrate the feasibility of modulating senescence to improve healthspan. Early preclinical and clinical studies provide encouraging evidence that reducing senescent cell burden or suppressing maladaptive SASP can alleviate tissue dysfunction and delay disease progression. Despite these advances, several critical challenges remain. First, the heterogeneity of SASP across cell types, tissues, and disease contexts is not yet fully resolved, necessitating more comprehensive profiling using single-cell and spatial multi-omics approaches. Second, the precise threshold at which SASP transitions from beneficial to detrimental is still undefined, limiting its translational application. Third, most current knowledge is derived from animal models, and discrepancies between experimental findings and human clinical outcomes need to be carefully addressed. Fourth, immune dysfunction in aging not only impairs senescent cell clearance but also interacts with SASP in a bidirectional manner. How to break this cycle remains an open question. Finally, clinical translation of senescence-targeted therapies faces obstacles such as off-target toxicity, delivery specificity, and long-term safety. Addressing these challenges will require integrated efforts combining systems biology, advanced biomaterials, and precision medicine approaches. In conclusion, SASP uses inflammaging as a common language to connect fundamental aging processes with clinical age-related diseases. As researchers unravel the cellular origins, composition, and regulatory networks of SASP, new therapeutic targets are emerging to break the vicious cycle of inflammaging. In the coming years, ongoing clinical trials and mechanistic studies will reveal the extent to which suppression of SASP-driven inflammation can delay or even reverse aging. Together, the three‑dimensional framework of duality, vicious cycle, and tissue specificity offers a rational basis for selecting context‑matched senotherapies. By taming SASP, the dark side of senescence, we may foster low-inflammation, resilient aged tissues, effectively interrupting the cascade from molecular damage to overt disease. As a mediator of inflammaging, SASP holds immense promise for advancing diagnostics and therapies for age-related diseases, marking a strategic shift from anti-aging to healthspan extension. Supplementary information Transparent Peer Review file Acknowledgements The authors thank BioRender.com for providing the platform used to create the scientific illustrations in this manuscript. Author contributions C. Sun, Q. Liu and Y. Zheng conceived the review. Q. Liu and Y. Zheng prepared the manuscript, and C. Sun critically reviewed, edited and revised it. All authors approved the final version of the manuscript. Peer review Peer review information Communications Biology thanks Akiko Takahashi and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editors Shona Mookerjee and Rosie Bunton-Stasyshyn. A peer review file is available. Funding This work was supported by National Natural Science Foundation of China. (81872207) and the Sichuan Science and Technology Bureau (2026NSFSC1596). Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. These authors contributed equally: Qian Liu, Yulin Zheng. Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s42003-026-10826-4. References Associated Data Supplementary Materials Transparent Peer Review file